News | December 09, 2023
Zepbound is now available in US for adults living with obesity
Express Scripts to add Zepbound to National Preferred Formulary
Express Scripts to add Zepbound to National Preferred Formulary
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
Lupin has been exclusively marketing these brands in the Indian market since July 2021
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
Subscribe To Our Newsletter & Stay Updated
